Concepedia

Author

A. John Ashcroft

University of Leeds

Also Known As

A J Ashcroft, A John Ashcroft, A. Ashcroft, A. J. Ashcroft, A. John Ashcroft, A.J Ashcroft, A.J. Ashcroft, Ali Alayan, Andrew Ashcroft, Andrew J Ashcroft

39

Publications

2.6K

Citations

20

H-Index

35

Concepts

All Affiliations

University of LeedsMid Yorkshire Hospitals NHS TrustUniversity of BirminghamSt James's University HospitalInstitute of Cancer Research
AJ

About

A. John Ashcroft is an author at University of Leeds specializing in medicine, hematology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

1.3K

2

Health Sciences

2

2

298

3

Cell Biology

1

1

143

4

Critical Care Medicine

1

1

35

5

Emergency Medicine

1

1

35

A. John Ashcroft

×

20

Publications

2.3K

Citations

18

H-Index

YearCitations

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory,

The Lancet

2010

566

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis

Faith E. Davies, Ann Dring, Cheng Li,

Blood

2003

226

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

Andy C. Rawstron, Faith E. Davies, Ranjit Dasgupta,

Blood

2002

209

Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin

A. John Ashcroft, Sheena Cruickshank, Peter I. Croucher,

Immunity

2003

180

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

Gareth J. Morgan, J. Anthony Child, Walter M. Gregory,

The Lancet Oncology

2011

161

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

Gordon Cook, Cathy Williams, Julia Brown,

The Lancet Oncology

2014

151

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Gordon Cook, A. John Ashcroft, David A. Cairns,

The Lancet Haematology

2016

147

CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells are increased whilst CD3<sup>+</sup>CD4<sup>−</sup>CD8<sup>−</sup>αβTCR<sup>+</sup> Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden

Sylvia Feyler, M von Lilienfeld-Toal, Sarah Jarmin,

British Journal of Haematology

2009

143

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory,

Blood

2012

130

Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma

Ranjit Dasgupta, Peter J. Adamson, Faith E. Davies,

Blood

2003

97

Page 1